274 related articles for article (PubMed ID: 31619231)
1. Co-mutations of TP53 and KRAS serve as potential biomarkers for immune checkpoint blockade in squamous-cell non-small cell lung cancer: a case report.
Fang C; Zhang C; Zhao WQ; Hu WW; Wu J; Ji M
BMC Med Genomics; 2019 Oct; 12(1):136. PubMed ID: 31619231
[TBL] [Abstract][Full Text] [Related]
2. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
[TBL] [Abstract][Full Text] [Related]
3. Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer.
Assoun S; Theou-Anton N; Nguenang M; Cazes A; Danel C; Abbar B; Pluvy J; Gounant V; Khalil A; Namour C; Brosseau S; Zalcman G
Lung Cancer; 2019 Jun; 132():65-71. PubMed ID: 31097096
[TBL] [Abstract][Full Text] [Related]
4. Potential Predictive Value of
Dong ZY; Zhong WZ; Zhang XC; Su J; Xie Z; Liu SY; Tu HY; Chen HJ; Sun YL; Zhou Q; Yang JJ; Yang XN; Lin JX; Yan HH; Zhai HR; Yan LX; Liao RQ; Wu SP; Wu YL
Clin Cancer Res; 2017 Jun; 23(12):3012-3024. PubMed ID: 28039262
[No Abstract] [Full Text] [Related]
5. The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity.
Liu C; Zheng S; Jin R; Wang X; Wang F; Zang R; Xu H; Lu Z; Huang J; Lei Y; Mao S; Wang Y; Feng X; Sun N; Wang Y; He J
Cancer Lett; 2020 Feb; 470():95-105. PubMed ID: 31644929
[TBL] [Abstract][Full Text] [Related]
6. Response to Checkpoint Inhibition in Non-Small Cell Lung Cancer with Molecular Driver Alterations.
Kauffmann-Guerrero D; Tufman A; Kahnert K; Bollmann BA; Reu S; Syunyaeva Z; Schneider C; Manapov F; Huber RM; Golpon H
Oncol Res Treat; 2020; 43(6):289-298. PubMed ID: 32268332
[TBL] [Abstract][Full Text] [Related]
7. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer.
Negrao MV; Skoulidis F; Montesion M; Schulze K; Bara I; Shen V; Xu H; Hu S; Sui D; Elamin YY; Le X; Goldberg ME; Murugesan K; Wu CJ; Zhang J; Barreto DS; Robichaux JP; Reuben A; Cascone T; Gay CM; Mitchell KG; Hong L; Rinsurongkawong W; Roth JA; Swisher SG; Lee J; Tsao A; Papadimitrakopoulou V; Gibbons DL; Glisson BS; Singal G; Miller VA; Alexander B; Frampton G; Albacker LA; Shames D; Zhang J; Heymach JV
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34376553
[TBL] [Abstract][Full Text] [Related]
8. Outcome of First-Line Treatment With Pembrolizumab According to KRAS/TP53 Mutational Status for Nonsquamous Programmed Death-Ligand 1-High (≥50%) NSCLC in the German National Network Genomic Medicine Lung Cancer.
Bischoff P; Reck M; Overbeck T; Christopoulos P; Rittmeyer A; Lüders H; Kollmeier J; Kulhavy J; Kemper M; Reinmuth N; Röper J; Janning M; Sommer L; Aguinarte L; Koch M; Wiesweg M; Wesseler C; Waller CF; Kauffmann-Guerrero D; Stenzinger A; Stephan-Falkenau S; Trautmann M; Lassmann S; Tiemann M; Klauschen F; Sebastian M; Griesinger F; Wolf J; Loges S; Frost N;
J Thorac Oncol; 2024 May; 19(5):803-817. PubMed ID: 38096950
[TBL] [Abstract][Full Text] [Related]
9. Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer.
Ng TL; Liu Y; Dimou A; Patil T; Aisner DL; Dong Z; Jiang T; Su C; Wu C; Ren S; Zhou C; Camidge DR
Cancer; 2019 Apr; 125(7):1038-1049. PubMed ID: 30548240
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of
Tønnesen EMT; Stougaard M; Meldgaard P; Lade-Keller J
J Clin Pathol; 2023 Dec; 77(1):54-60. PubMed ID: 36410939
[TBL] [Abstract][Full Text] [Related]
11. The prevalence and prognostic value of KRAS co-mutation subtypes in Chinese advanced non-small cell lung cancer patients.
Cai D; Hu C; Li L; Deng S; Yang J; Han-Zhang H; Li M
Cancer Med; 2020 Jan; 9(1):84-93. PubMed ID: 31709742
[TBL] [Abstract][Full Text] [Related]
12. KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer.
Liu C; Zheng S; Wang Z; Wang S; Wang X; Yang L; Xu H; Cao Z; Feng X; Xue Q; Wang Y; Sun N; He J
Cancer Commun (Lond); 2022 Sep; 42(9):828-847. PubMed ID: 35811500
[TBL] [Abstract][Full Text] [Related]
13. Novel Kras-mutant murine models of non-small cell lung cancer possessing co-occurring oncogenic mutations and increased tumor mutational burden.
Salehi-Rad R; Li R; Tran LM; Lim RJ; Abascal J; Momcilovic M; Park SJ; Ong SL; Shabihkhani M; Huang ZL; Paul M; Shackelford DB; Krysan K; Liu B; Dubinett SM
Cancer Immunol Immunother; 2021 Aug; 70(8):2389-2400. PubMed ID: 33507343
[TBL] [Abstract][Full Text] [Related]
14. Non-small-cell lung cancer patients harboring
Zhang C; Wang K; Lin J; Wang H
Future Oncol; 2022 Sep; 18(27):3031-3041. PubMed ID: 36065989
[TBL] [Abstract][Full Text] [Related]
15. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
16. Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes.
Aredo JV; Padda SK; Kunder CA; Han SS; Neal JW; Shrager JB; Wakelee HA
Lung Cancer; 2019 Jul; 133():144-150. PubMed ID: 31200821
[TBL] [Abstract][Full Text] [Related]
17. KRAS G12D mutation predicts lower TMB and drives immune suppression in lung adenocarcinoma.
Gao G; Liao W; Ma Q; Zhang B; Chen Y; Wang Y
Lung Cancer; 2020 Nov; 149():41-45. PubMed ID: 32956987
[TBL] [Abstract][Full Text] [Related]
18. Distribution of KRAS, DDR2, and TP53 gene mutations in lung cancer: An analysis of Iranian patients.
Fathi Z; Mousavi SAJ; Roudi R; Ghazi F
PLoS One; 2018; 13(7):e0200633. PubMed ID: 30048458
[TBL] [Abstract][Full Text] [Related]
19. Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in
West HJ; McCleland M; Cappuzzo F; Reck M; Mok TS; Jotte RM; Nishio M; Kim E; Morris S; Zou W; Shames D; Das Thakur M; Shankar G; Socinski MA
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35190375
[TBL] [Abstract][Full Text] [Related]
20. A single institution study evaluating outcomes of PD-L1 high KRAS-mutant advanced non-small cell lung cancer (NSCLC) patients treated with first line immune checkpoint inhibitors.
Kartolo A; Feilotter H; Hopman W; Fung AS; Robinson A
Cancer Treat Res Commun; 2021; 27():100330. PubMed ID: 33581492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
